Últimas noticias sobre Alibaba Gr Hldgs (OTC:BABAF) Bolsa

Alibaba is the world's largest online and mobile commerce company as measured by gross merchandise volume. It operates China's online marketplaces, including Taobao (consumer-to-consumer) and Tmall (business-to-consumer). The China commerce retail division is the most valuable cash flow-generating business at Alibaba. Additional revenue sources include China commerce wholesale, international commerce retail/wholesale, local consumer services, cloud computing, digital media and entertainment platforms, Cainiao logistics services, and innovation initiatives/other.

Equities

News

Markets

BABA

ALIBABA GROUP HOLDING LTD by Alibaba Group Holding Limited

BABAF

Las acciones de Alibaba suben con fuerza gracias a su IA avanzada. ¿Cómo impactará esto en su próximo informe de ganancias?

Acciones de Alibaba (BABA) en Hong Kong suben tras avances en inteligencia artificial

Asia

Long Ideas

Tech

Trading Ideas

NVDA

ByteDance invertirá en chips Nvidia en 2025 para potenciar su IA. Descubre su estrategia en la carrera global por la inteligencia artificial.

ByteDance apuesta por la IA: Inversión millonaria en chips Nvidia para 2025

Alibaba Group Holding Ltd

Wayfair Announced Muse, Its Latest Innovation In Personalized Home Shopping

B of A Securities analyst Curtis Nagle maintains Tempur Sealy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPX#NYSE">TPX</a>) with a Buy and raises the price target from $73 to $79.

Price Target

Analyst Ratings

B of A Securities Maintains Buy on Tempur Sealy Intl, Raises Price Target to $79

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Palvella Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PVLA#NASDAQ">PVLA</a>) with a Buy and maintains $38 price target.

Reiteration

PVLA

HC Wainwright & Co. Reiterates Buy on Palvella Therapeutics, Maintains $38 Price Target

Guidance

FIS Expects Full-year 2025 Revenue Of $10.435B - $10.495B (Est $10.601B), Adjusted EPS Of $5.70 - $5.80 (Est $5.72)

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Oppenheimer analyst Tyler Batory downgraded the rating for Playa Hotels &amp; Resorts N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLYA#NASDAQ">PLYA</a>) from Outperform to Perform. Playa Hotels shares closed at $13.24 on Monday. <a href="https://www.benzinga.com/quote/PLYA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst Ameet Thakkar downgraded Fluence Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) from Outperform to Market Perform and lowered the price target from $22 to $10. Fluence Energy shares closed at $13.07 on Monday. <a href="https://www.benzinga.com/quote/FLNC/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Goldman Sachs analyst Paul Choi downgraded the rating for Dynavax Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DVAX#NASDAQ">DVAX</a>) from Neutral to Sell and slashed the price target from $15 to $12. Dynavax shares closed at $13.20 on Monday. <a href="https://www.benzinga.com/quote/DVAX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Piper Sandler analyst Christopher Raymond downgraded Q32 Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTTB#NASDAQ">QTTB</a>) from Overweight to Neutral and cut the price target from $20 to $4. Q32 Bio shares closed at $3.18 on Monday. <a href="https://www.benzinga.com/quote/QTTB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>DA Davidson analyst Matt Summerville downgraded the rating for Columbus McKinnon Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCO#NASDAQ">CMCO</a>) from Buy to Neutral and announced a $35 price target. Columbus McKinnon shares closed at $35.48 on Monday. <a href="https://www.benzinga.com/quote/CMCO/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CMCO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="593" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11070620/image-91-1024x593.png" alt="" class="wp-image-776431" style="width:589px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11070620/image-91-1024x593.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11070620/image-91-300x174.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11070620/image-91-768x445.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11070620/image-91.png 1108w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43592071/top-3-tech-stocks-that-may-jump-this-month">Top 3 Tech Stocks That May Jump This Month</a></li>
</ul>

Downgrades

Pre-Market Outlook

CMCO

DVAX

FLNC

PLYA

QTTB

This Columbus McKinnon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

TVTX

Travere Therapeutics Announced The Completion Of Its Type C Meeting With The U.S. Food And Drug Administration And Plans To Submit A Supplemental New Drug Application Seeking Traditional Approval Of Filspari For Focal Segmental Glomerulosclerosis

Outlook
For 2025, management expects revenue between $390 million and $430 million, inclusive of contributions from the E2E acquisition. Management expects Non-GAAP operating margins to be at least 10% at the low end of this revenue range, with improved free cash flow compared to 2024.

CRNT

Ceragon 2025 Forecast: Revenue To be $390M–$430M Vs. $415.2M Est.; Margins Expected At 10% Minimum

Ethereum&#8216;s (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) underperformance compared to other big cryptocurrencies has caused a stir in the crypto community, but its leadership maintains that its culture is the key <a href="https://www.benzinga.com/money/ethereum-eth-price-predictions">to long-term success.</a>
What Happened: According to Devansh Mehta, public goods and governance lead at the Ethereum Foundation, Ethereum&#8217;s strong, community-driven culture focused on openness, transparency and challenging authority is Ethereum&#8217;s core strength.
In an interview with Benzinga, Mehta said this unique culture attracts top-tier talent and fosters innovation, giving Ethereum a significant advantage over competitors.
Mehta emphasized that Ethereum&#8217;s strength lies not just in its technology, but in the collective values of its contributors. 
&#8220;Ethereum wins because of its community,&#8221; Mehta stated, highlighting the presence of &#8220;top notch teams all working in the same ecosystem, sharing similar values of openness, transparency and rebelliousness against authority.&#8221;
He contrasted Ethereum&#8217;s culture with that of other blockchain projects, stating, &#8220;Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>) doesn&#8217;t have that &#8211; a lot of their code and wallets cant be verified by anyone. XRP (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/xrp/usd">XRP</a>) isn&#8217;t so much for the rebels &#8211; its value prop is working with governments.&#8221; 
Mehta believes that the &#8220;mavericks and the rebels&#8221; are the driving force behind shareholder value creation in the 21st century.
Mehta urged Ethereum investors to focus on the quality and values of the individuals within the Ethereum ecosystem, rather than solely focusing on price fluctuations. 
&#8220;My message to ETH investors would be to look past the immediate price and instead search for intangibles like: what is the quality of people in the EVM ecosystem? Are the people working in the Ethereum universe people that i would bet on? How supportive is Ethereum of its best builders?&#8221;
Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43605114/dave-portnoy-holds-millions-in-bitcoin-and-xrp-but-heres-why-he-concluded-his-heart-is-too-big-for-this-space">Dave Portnoy Holds Millions In Bitcoin And XRP, But Here&#8217;s Why He Concluded His Heart Is &#8216;Too Big For This Space&#8217;</a>
Why It Matters: Mehta has been recently appointed to the top post amid recent events have cast a shadow on this Ethereum&#8217;s narrative.
Leadership struggles and investor concerns regarding Ethereum&#8217;s long-term viability have prompted Ethereum creator Vitalik Buterin to assert his control over the Foundation&#8217;s future direction. 
Buterin took to social media to <a href="https://x.com/VitalikButerin/status/1881680518934384676">emphasize</a> that he will personally oversee any upcoming leadership changes, while ensuring that his decisions are not influenced by outside pressure.
The increased pressure from investors stems from growing unease about the perceived inaction of the Ethereum Foundation amid declining market legitimacy. 
This internal discord has even led to the departure of veteran developer Eric Conner, who <a href="https://x.com/econoar/status/1881554156261122535">expressed </a>frustration with the leadership&#8217;s disconnect from the community&#8217;s needs and values. 
Conner stated his hope that leadership might eventually realign with the community, but felt compelled to step away for now.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/02/43600376/netvrk-launches-silkai-aims-to-deliver-hyperintelligent-ai-agents-to-metaverse">NetVRk Launches SilkAI, Aims To Deliver Hyperintelligent AI Agents To Metaverse</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

$SOL

$XRP

Ethereum Has A Key Strength That XRP, Solana Don't Have, Expert Says

2025 Business Outlook
<ul>
<li>Full-year 2025 Adjusted EBITDA(1)(3) to be in a range of $1.90 billion to $1.95 billion</li>
<li>Total operating expenses(4) to be in a range of $900 million to $925 million</li>
<li>Growth capital expenditures of at least $400 million</li>
<li>Maintenance capital expenditures of approximately $150 million</li>
</ul>

Sunoco Sees FY25 Adjusted EBITDA $1.90B-$1.95B, Growth Capex Of At least $400M

Biotech

Large Cap

Health Care

General

Health Canada Has Approved Merck's Keytruda (Pembrolizumab) For Adult Patients With Resectable Stage II, IIIA, or IIIB (T3-4N2) Non-Small Cell Lung Carcinoma In Combination With Platinum-Containing Chemotherapy As Neoadjuvant Treatment, And Then Continued As Monotherapy As Adjuvant Treatment After Surgery

VYGR

Voyager Therapeutics Announced It Has Decided To Assess Alternate Payloads Related To Its Gene Therapy Program For Superoxide Dismutase 1 (SOD1) Amyotrophic Lateral Sclerosis (ALS)

<h3>Gainers</h3>
<ul>
<li>BJ's Restaurants (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJRI#NASDAQ">BJRI</a>) stock increased by 24.2% to $43.99 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.0 billion. </li>
<li>China Liberal Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) shares rose 20.27% to $0.13. The market value of their outstanding shares is at $35.1 million. </li>
<li>Interactive Strength (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRNR#NASDAQ">TRNR</a>) shares moved upwards by 16.99% to $1.79. The market value of their outstanding shares is at $2.4 million. </li>
<li>Springview Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPHL#NASDAQ">SPHL</a>) stock moved upwards by 11.41% to $2.05. The company's market cap stands at $23.5 million. </li>
<li>Jiuzi Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZXN#NASDAQ">JZXN</a>) shares rose 10.76% to $3.6. The company's market cap stands at $32.5 million. </li>
<li>Lincoln Educational Servs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LINC#NASDAQ">LINC</a>) stock rose 8.88% to $18.99. The market value of their outstanding shares is at $597.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>MGO Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGOL#NASDAQ">MGOL</a>) shares decreased by 25.1% to $0.52 during Tuesday's pre-market session. The company's market cap stands at $4.8 million. </li>
<li>PetMed Express (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PETS#NASDAQ">PETS</a>) shares declined by 21.45% to $4.14. The market value of their outstanding shares is at $85.5 million. The company's, Q3 earnings came out yesterday. </li>
<li>Hour Loop (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOUR#NASDAQ">HOUR</a>) shares declined by 12.29% to $2.0. The market value of their outstanding shares is at $70.2 million. </li>
<li>Damon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DMN#NASDAQ">DMN</a>) shares decreased by 9.18% to $0.49. The company's market cap stands at $10.7 million. </li>
<li>SRM Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRM#NASDAQ">SRM</a>) shares fell 7.24% to $0.29. The market value of their outstanding shares is at $4.6 million. </li>
<li>Youdao (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAO#NYSE">DAO</a>) shares fell 7.21% to $10.3. The company's market cap stands at $1.2 billion. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

BJRI

CLEU

HOUR

JZXN

LINC

MGOL

PETS

SPHL

TRNR

12 Consumer Discretionary Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Lipella Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIPO#NASDAQ">LIPO</a>) stock moved upwards by 64.9% to $5.03 during Tuesday's pre-market session. The company's market cap stands at $6.0 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) stock moved upwards by 50.47% to $0.22. The market value of their outstanding shares is at $7.7 million. </li>
<li>Third Harmonic Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRD#NASDAQ">THRD</a>) stock increased by 20.21% to $5.59. The market value of their outstanding shares is at $251.8 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock increased by 15.78% to $2.64. The company's market cap stands at $5.9 million. </li>
<li>Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) shares increased by 15.26% to $1.51. The market value of their outstanding shares is at $6.0 million. </li>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) shares rose 10.53% to $0.11. The company's market cap stands at $6.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Prelude Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRLD#NASDAQ">PRLD</a>) shares fell 17.4% to $0.9 during Tuesday's pre-market session. The market value of their outstanding shares is at $49.5 million. </li>
<li>Stoke Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STOK#NASDAQ">STOK</a>) shares declined by 11.3% to $9.11. The market value of their outstanding shares is at $482.5 million. </li>
<li>DIH Holding US (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DHAI#NASDAQ">DHAI</a>) stock decreased by 10.75% to $0.61. The market value of their outstanding shares is at $21.5 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) stock declined by 10.62% to $4.8. The market value of their outstanding shares is at $3.2 million. </li>
<li>Invivyd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IVVD#NASDAQ">IVVD</a>) shares fell 9.56% to $1.42. The market value of their outstanding shares is at $169.8 million. </li>
<li>Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) stock declined by 9.0% to $0.44. The company's market cap stands at $1.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AVGR

BDRX

CNSP

DHAI

IVVD

LIPO

LIXT

OCEA

PRLD

SLXN

STOK

THRD

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Regeneron Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for linvoseltamab for the treatment of adult patients with relapsed/refractory (R/R) multiple myeloma (MM) who have received at least four prior lines of therapy or those who received three prior lines of therapy and are refractory to the last line of therapy. The target action date for the FDA decision is July 10, 2025.
Acceptance of the BLA resubmission follows the resolution of third-party fill/finish manufacturing issues, which was the sole approvability issue identified by the FDA in the previous submission. The BLA is supported by data from the pivotal <a href="https://www.globenewswire.com/Tracker?data=032VzgfH3Zwknll4UBWp8zhL6nLWeVfQ1uAUbAV9jnbajCy8FTsCvmUFAcFkm2eV2t8IsNs_EENj37PPYz-UlBqu0UDpGan2Fb0QI2pnGVLOoY0TTAijCF94frYMM2vmpGyaZQXMcarXAK7CoIb_u_KN_JrMo6DgxNNL8nroMNCP8WxgVYfRst4Y4E16DQxgOhjw4zyPn14Rb0E4YfjvaA==">LINKER-MM1</a> trial investigating linvoseltamab in R/R MM, and linvoseltamab is also under <a href="https://www.globenewswire.com/Tracker?data=VbdWV_4JC1drSn1toq6OXZrfe0cN2O7_-1sX29HBZEhwCraOE4NHWui62si87wvGd_evR2y4lyNT3suHRjq5Unu5_dIpapz8ZNlk4DAEdaql_zXgO3uLdRsY7W_5_Qh1i4ibQb8-BPGiH7K1yDxOsY3Mq-p-i3oU-iiMXVErUzjEtQlvuxgmzOjmgqrPDBM6FoGMQDUJhRnDgmdZPq7OZw==">review</a> by the&nbsp;European Medicines Agency (EMA) for the same patient population.
Linvoseltamab is investigational and has not been approved by any regulatory authority.

Government

Regulations

REGN

Regeneron Clears Manufacturing Hurdle as FDA Sets July 2025 Decision Date for Linvoseltamab in Multiple Myeloma

<h3>Gainers</h3>
<ul>
<li>Vast Renewables (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTE#NASDAQ">VSTE</a>) shares moved upwards by 46.4% to $1.01 during Tuesday's pre-market session. The market value of their outstanding shares is at $30.2 million. </li>
<li>Rain Enhancement (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAIN#NASDAQ">RAIN</a>) shares moved upwards by 17.64% to $3.8. The company's market cap stands at $28.7 million. </li>
<li>Universal Logistics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULH#NASDAQ">ULH</a>) shares rose 16.85% to $34.74. The company's market cap stands at $914.2 million. As per the news, the Q4 earnings report came out 3 days ago. </li>
<li>Elong Power Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELPW#NASDAQ">ELPW</a>) stock moved upwards by 8.08% to $1.07. The company's market cap stands at $53.5 million. </li>
<li>Satellogic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SATL#NASDAQ">SATL</a>) stock increased by 7.76% to $4.86. The company's market cap stands at $465.5 million. </li>
<li>Quanex Building Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NX#NYSE">NX</a>) stock moved upwards by 6.51% to $22.89. The company's market cap stands at $1.0 billion. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) shares declined by 38.0% to $8.1 during Tuesday's pre-market session. The market value of their outstanding shares is at $1.0 billion. The company's, Q1 earnings came out yesterday. </li>
<li>New Century Logistics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCEW#NASDAQ">NCEW</a>) shares declined by 21.49% to $1.06. The market value of their outstanding shares is at $22.7 million. </li>
<li>Momentus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>) stock fell 10.42% to $4.0. The company's market cap stands at $11.1 million. </li>
<li>Columbus McKinnon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCO#NASDAQ">CMCO</a>) shares declined by 8.55% to $32.45. The company's market cap stands at $930.9 million. As per the news, the Q3 earnings report came out yesterday. </li>
<li>FBS Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBGL#NASDAQ">FBGL</a>) stock decreased by 7.0% to $1.33. The company's market cap stands at $17.9 million. </li>
<li>Samfine Creation Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SFHG#NASDAQ">SFHG</a>) shares fell 6.85% to $0.9. The market value of their outstanding shares is at $20.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ELPW

FBGL

MNTS

NCEW

RAIN

SATL

SFHG

VSTE

12 Industrials Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Cyngn (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares moved upwards by 38.4% to $0.26 during Tuesday's pre-market session. The market value of their outstanding shares is at $5.4 million. </li>
<li>Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) stock rose 14.3% to $62.26. The company's market cap stands at $8.5 billion. As per the press release, Q4 earnings came out yesterday. </li>
<li>Bit Origin (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTOG#NASDAQ">BTOG</a>) shares moved upwards by 10.04% to $0.54. The market value of their outstanding shares is at $4.5 million. </li>
<li>UTime (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTO#NASDAQ">WTO</a>) stock rose 9.35% to $0.29. The company's market cap stands at $7.4 million. </li>
<li>Perfect (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PERF#NYSE">PERF</a>) shares rose 7.98% to $2.3. The company's market cap stands at $234.2 million. </li>
<li>Glimpse Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRAR#NASDAQ">VRAR</a>) shares rose 7.34% to $1.9. The company's market cap stands at $38.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Harmonic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLIT#NASDAQ">HLIT</a>) shares decreased by 27.4% to $8.07 during Tuesday's pre-market session. The company's market cap stands at $940.3 million. As per the news, the Q4 earnings report came out yesterday. </li>
<li>Brand Engagement Network (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNAI#NASDAQ">BNAI</a>) stock declined by 18.72% to $0.56. The company's market cap stands at $21.4 million. </li>
<li>Viasat (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>) shares decreased by 16.84% to $9.29. The market value of their outstanding shares is at $1.1 billion. As per the news, the Q3 earnings report came out 3 days ago. </li>
<li>Socket Mobile (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCKT#NASDAQ">SCKT</a>) shares declined by 13.48% to $1.22. The company's market cap stands at $9.2 million. </li>
<li>Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) stock fell 9.49% to $22.05. The market value of their outstanding shares is at $5.4 billion. The company's, Q4 earnings came out yesterday. </li>
<li>Cloudastructure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSAI#NASDAQ">CSAI</a>) stock decreased by 8.68% to $11.27. The company's market cap stands at $164.4 million. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMKR

BNAI

BTOG

CSAI

HLIT

LSCC

PERF

SCKT

VRAR

VSAT

12 Information Technology Stocks Moving In Tuesday's Pre-Market Session

Third Harmonic Bio Says THB335 Phase 1 Data Supports Advancement Into Phase 2 Clinical Trial In Chronic Spontaneous Urticaria (CSU)

Distribution
On January 27, 2025, the Board of Directors of SUN's general partner declared a distribution for the fourth quarter of 2024 of $0.8865 per unit, or $3.5460 per unit on an annualized basis. The distribution will be paid on February 19, 2025, to common unitholders of record on February 7, 2025.
The Partnership is targeting a distribution growth rate of at least 5% for 2025 and will announce future increases quarterly.

Dividends

Sunoco Targets Distribution Growth Rate Of At Least 5% For 2025 And Will Announce Future Increases Quarterly

Needham analyst Joseph Stringer reiterates Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from Hold to Hold.

VRTX

Needham Reiterates Hold on Vertex Pharmaceuticalsto Hold

Masco Sees FY25 Adj. EPS Of $4.20 - $4.45 Vs. $4.40 Est.

Baron Emerging Markets Fund: Q4 2024 Top Contributors And Detractors

Alibaba: Big Winner In DeepSeek Saga

Alibaba: Will Qwen 2.5 Max Lift The Stock Back To Glory?

Martin Currie Emerging Markets Fund Q4 2024 Commentary

DeepSeek Should Really Be Called ShallowSeek -- Nvidia Remains A 'Buy'

Alibaba: Forget The Trade War, Buy China's ChatGPT Moment

Nvidia: Buying The Dip Could Be Very Painful

Alibaba: Expect Shares To Outperform, Again

Alibaba Said Its AI Outperformed DeepSeek: This Is Why The Stock Is A Buy

Tracking David Tepper's Appaloosa Management Portfolio - Q4 2024 Update

AMZN

ASML

ASMLF

BAIDF

BIDU

EXEEL

EXEEW

EXEEZ

GOOG

GOOGL

HXSCF

JDCMF

KWEB

LYFT

LZRFY

MPNGF

MPNGY

MSFT

ORCL

QCOM

SSNLF

TCEHY

TSLA

TSMWF

UBER

WYNN

Alibaba Gr Hldgs

Comments

Alibaba Gr Hldgs

Noticias

Últimas noticias sobre Alibaba Gr Hldgs (OTC:BABAF) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL